Patrys FY23 Annual Report

ASX Announcements

Patrys has today released its Annual Report for the 2022-23 Financial Year (FY23).

Highlights include:

  • Successful completion of the PAT-DX1 engineering run
  • New data demonstrating PAT-DX1/radiation combination improves brain cancer survival in a pre-clinical model
  • PAT-DX1 GLP toxicology reports received
  • New PAT-DX3 data demonstrating synthetic lethality
  • Completion of the master cell bank and integration run for PAT-DX3
  • The appointment of Dr. Charmaine Gittleson as Chairman

Click here to read the full report.